Global Central Nervous System (CNS) Drug Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Central Nervous System (CNS) Drug Market Research Report 2024
Central nervous system (CNS) disease is a broad category of conditions in which the brain does not function as it should, limiting health and the ability to function. The condition may be an inherited metabolic disorder; the result of damage from an infection, a degenerative condition, stroke, a brain tumor or other problem; or arise from unknown or multiple factors. Movement disorders such as Parkinson’s disease, dystonia, and essential tremor are central nervous system conditions. What they have in common is the loss of sufficient, intact nervous system circuits that orchestrate functions as varied as memory formation (in Alzheimer’s) or voluntary motion (in movement disorders).
According to Mr Accuracy reports’s new survey, global Central Nervous System (CNS) Drug market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Central Nervous System (CNS) Drug market research.
Key companies engaged in the Central Nervous System (CNS) Drug industry include Johnson & Johnson, Pfizer Inc, Novartis AG, GSK, Eli Lilly, Teva, Otsuka Pharmaceutical Co., Ltd, Biogen Inc and Boehringer Ingelheim, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Central Nervous System (CNS) Drug were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Central Nervous System (CNS) Drug market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Central Nervous System (CNS) Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

Johnson & Johnson
Pfizer Inc
Novartis AG
GSK
Eli Lilly
Teva
Otsuka Pharmaceutical Co., Ltd
Biogen Inc
Boehringer Ingelheim
Roche
UCB
Tekeda
Shanghai Fosun
Jiangsu Nhwa Pharmaceutical Co., Ltd.
Segment by Type
Prescription Drugs
OTC
MS Therapeutics
Antipsychotic Drugs
Depression Drugs
Epilepsy Drugs
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Central Nervous System (CNS) Drug report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Central Nervous System (CNS) Drug market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Central Nervous System (CNS) Drug market research.
Key companies engaged in the Central Nervous System (CNS) Drug industry include Johnson & Johnson, Pfizer Inc, Novartis AG, GSK, Eli Lilly, Teva, Otsuka Pharmaceutical Co., Ltd, Biogen Inc and Boehringer Ingelheim, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Central Nervous System (CNS) Drug were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Central Nervous System (CNS) Drug market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Central Nervous System (CNS) Drug market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company
Johnson & Johnson
Pfizer Inc
Novartis AG
GSK
Eli Lilly
Teva
Otsuka Pharmaceutical Co., Ltd
Biogen Inc
Boehringer Ingelheim
Roche
UCB
Tekeda
Shanghai Fosun
Jiangsu Nhwa Pharmaceutical Co., Ltd.
Segment by Type
Prescription Drugs
OTC
Segment by Application
MS Therapeutics
Antipsychotic Drugs
Depression Drugs
Epilepsy Drugs
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Central Nervous System (CNS) Drug report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
